Loading
In 597 Iranian women given a locally made copy of trastuzumab after breast cancer surgery, the commonest side effects were reduced heart pumping function, nerve damage and nausea, and the authors judged it generally well tolerated.
Post-marketing surveillance of AryoTrust, the trastuzumab made by AryoGen in Iran, in women with HER2-positive non-metastatic breast cancer who had had adjuvant chemotherapy and then received trastuzumab every three weeks for nine cycles, from February 2017 to August 2022 (NCT06021379). Safety data were collected in booklets.
Routine-use safety data for a trastuzumab made in Iran, collected at 15 sites in ten cities across the country.
Shares Biosimilar, Trastuzumab, HER2, HER2-positive breast cancer.
Shares AryoGen Pharmed, Biosimilar.
Shares Biosimilar, Trastuzumab, HER2, HER2-positive breast cancer.
Shares AryoGen Pharmed, Biosimilar, HER2-positive breast cancer.
Shares AryoGen Pharmed, Biosimilar.
Shares Trastuzumab, HER2, HER2-positive breast cancer.
Shares Trastuzumab, HER2, HER2-positive breast cancer.
Shares AryoGen Pharmed, Biosimilar, Trastuzumab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/